View Older Stories View More Recent Stories

Feb 12, 2025 09:58AM Gilead Sciences (GILD) PT Raised to $110 at Piper Sandler Following a 'Very Healthy Finish To 2024'
Feb 12, 2025 06:55AM Oppenheimer Reiterates Outperform Rating on Gilead Sciences (GILD)
Feb 12, 2025 03:21AM Stocks expected to have increasing option volume: GILD LYFT Z SMCI UPST CAR CSCO APP HOOD CME WMB TTD EXC KHC VTR BIIB MGM BROS
Feb 11, 2025 04:58PM After-hours movers: Lyft , Super Micro Computer, Upstart Holdings, DoorDash and more
Feb 11, 2025 04:06PM Gilead Sciences (GILD) Declares $0.79 Quarterly Dividend; 3.3% Yield
Feb 11, 2025 04:04PM Gilead Sciences (GILD) Tops Q4 EPS by 19c, Offers Guidance
Feb 10, 2025 10:23AM Gilead Sciences (GILD) call put ratio 1 call to 1.2 puts into quarter results
Feb 10, 2025 05:28AM Gilead Sciences (GILD) February 14 weekly 96 straddle into quarter results
Jan 30, 2025 08:00AM Cognizant (CTSH) and Gilead (GILD) Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Jan 13, 2025 11:14AM Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
Jan 10, 2025 05:23AM Morgan Stanley Upgrades Gilead Sciences (GILD) to Overweight
Jan 7, 2025 09:10AM Gilead Sciences (GILD) PT Lowered to $83 as RBC Capital Highlights Biktarvy's Strong Profile
Dec 19, 2024 02:00PM 4 themes and 4 key biotech stocks for 2025: Jefferies
Dec 19, 2024 11:16AM RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
Dec 19, 2024 08:01AM Assembly Biosciences (ASMB) Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
Dec 17, 2024 08:33AM Gilead Sciences (GILD) Granted FDA Breakthrough Therapy Designation to Trodelvy
Dec 17, 2024 07:02AM Gilead Sciences (GILD) and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Dec 17, 2024 06:42AM Bernstein: 'We Are Bullish on Gilead Sciences (GILD)'
Dec 13, 2024 06:37AM Gilead Sciences (GILD) Received Positive CHMP Opinion for Seladelpar
Dec 11, 2024 06:39AM Bernstein SocGen Group Reiterates Outperform Rating on Gilead Sciences (GILD) Following HIV Day
Dec 11, 2024 06:31AM Deutsche Bank Reiterates Hold Rating on Gilead Sciences (GILD)
Dec 11, 2024 06:21AM Gilead Sciences (GILD) PT Raised to $99 at Leerink Partners
Dec 9, 2024 04:36PM Gilead Sciences (GILD): Longest Follow-Up Data Reported for Kite’s Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Dec 9, 2024 04:03PM Gilead Sciences (GILD) PT Raised to $115 at Oppenheimer
Dec 3, 2024 07:00AM Gilead Sciences (GILD) and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Nov 30, 2024 04:00AM Is Trump 2.0 good or bad for healthcare stocks?
Nov 27, 2024 05:01PM Gilead Sciences (GILD) Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Nov 18, 2024 06:55AM Gilead Sciences (GILD) PT Raised to $84 at RBC Capital
Nov 15, 2024 11:01AM Gilead Sciences (GILD) Reports Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Nov 13, 2024 04:08PM Citi Starts Gilead Sciences (GILD) at Buy
Nov 13, 2024 06:46AM Gilead Sciences (GILD) Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention
Nov 7, 2024 08:42AM Gilead Sciences (GILD) PT Raised to $105 at Oppenheimer
Nov 7, 2024 07:52AM Gilead Sciences (GILD) PT Raised to $105 at Piper Sandler
Nov 6, 2024 04:05PM Gilead Sciences (GILD) Tops Q3 EPS by 51c; raises guidance
Nov 5, 2024 02:21PM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Oct 21, 2024 07:55AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Oct 21, 2024 06:32AM TD Cowen Reiterates Buy Rating on Gilead Sciences (GILD)
Oct 21, 2024 06:19AM Leerink Partners Upgrades Gilead Sciences (GILD) to Outperform
Oct 21, 2024 05:59AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 21, 2024 05:58AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 18, 2024 10:45AM TD Cowen Reiterates Buy Rating on Gilead Sciences (GILD)
Oct 10, 2024 05:25AM Wells Fargo Reiterates Overweight Rating on Gilead Sciences (GILD)
Oct 9, 2024 08:35AM Gilead Sciences (GILD) to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek
Oct 7, 2024 11:00AM Gilead Sciences (GILD) Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Oct 2, 2024 08:32AM Gilead Sciences (GILD) Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countri
Sep 23, 2024 08:45AM Barclays on Gilead Sciences (GILD): 'Modest positive read-through for Trodelvy positioning in 2L+ HR/Her2- breast cancer'
Sep 23, 2024 08:03AM Jefferies on Gilead Sciences (GILD): 'Competitor Dato surprise setback in breast cancer, new incremental (+) for GILD'
Sep 13, 2024 06:50AM Mizuho Reiterates Outperform Rating on Gilead Sciences (GILD)
Sep 12, 2024 10:06AM Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)
View More Recent Stories View Older Stories